Tudor Investment Corp ET AL Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Tudor Investment Corp ET AL bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 22,649 shares of the company's stock, valued at approximately $427,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PCRX. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Pacira BioSciences by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 56,385 shares of the company's stock valued at $1,062,000 after purchasing an additional 8,636 shares in the last quarter. Nisa Investment Advisors LLC grew its position in Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. Gagnon Securities LLC grew its position in Pacira BioSciences by 4.8% in the 4th quarter. Gagnon Securities LLC now owns 321,743 shares of the company's stock worth $6,062,000 after purchasing an additional 14,800 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares during the last quarter. Finally, Caitlin John LLC grew its position in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after purchasing an additional 1,776 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Trading Down 0.1%

NASDAQ:PCRX traded down $0.03 during trading hours on Monday, hitting $25.09. The stock had a trading volume of 1,826,092 shares, compared to its average volume of 966,956. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -12.36 and a beta of 0.56. The business's 50 day moving average is $24.73 and its 200-day moving average is $22.17.

Analyst Ratings Changes

Several analysts have issued reports on PCRX shares. HC Wainwright raised their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and raised their price target for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Royal Bank of Canada restated a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Needham & Company LLC decreased their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.